• Review opportunities for biopharma companies to continue listening to patients long after a drug has launched, particularly as pediatric patients become adults and their needs evolve • Turn patient and physician insights into new formulations, new doses, and new storage options • Go beyond scientific innovation to address changing patient needs through ambassador and other programs